Replies to post #14531 on MannKind Corp. (MNKD)

[Denise Chanterelle]

Same analyst ..... was wrong before..
Same guy said that Afrezza would probably not be approved. No credibility.

Piper Jaffray analyst Joshua Schimmer noted that MannKind faces a "number of obstacles" in the U.S. Food and Drug Administration's (FDA) review of the Afrezza Dreamboat insulin inhaler. Schimmer reported that it is "doubtful" for the company to gain positive recommendation from the advisory panel. The analyst commented that a closer read of the FDA staff briefing documents suggest that the agency "has enough concerns that only a cleanly positive vote will enable approval without additional requirements."